CB2 Receptor and Atherosclerosis in Mice
Author Information
Author(s): Willecke Florian, Zeschky Katharina, Ortiz Rodriguez Alexandra, Colberg Christian, Auwärter Volker, Kneisel Stefan, Hutter Melanie, Lozhkin Andrey, Hoppe Natalie, Wolf Dennis, von zur Mühlen Constantin, Moser Martin, Hilgendorf Ingo, Bode Christoph, Zirlik Andreas
Primary Institution: Department of Cardiology, University of Freiburg, Freiburg, Germany
Hypothesis
Does cannabinoid receptor 2 (CB2) signaling modulate atherogenesis in mice?
Conclusion
The study found that neither activation nor deletion of the CB2 receptor significantly affects atherogenesis in mice.
Supporting Evidence
- CB2 receptor activation did not change the size of atherosclerotic lesions in treated mice.
- Both CB2 deficient and normal mice developed similar atherosclerotic lesions.
- The study used a selective CB2 agonist, JWH-133, which was bioavailable in vivo.
- Inflammatory cytokine expression was not significantly altered by CB2 receptor stimulation.
Takeaway
The study tested if a specific receptor in the body helps with heart disease in mice, but it turns out it doesn't really make a difference.
Methodology
LDLR−/− mice were treated with a CB2 receptor agonist or vehicle and fed a high-cholesterol diet for 16 weeks, followed by analysis of atherosclerotic lesions.
Limitations
The study may not have used a sufficient dose of the CB2 agonist to observe effects, and it focused only on specific stages of atherosclerosis.
Participant Demographics
Male LDLR−/− mice, aged six weeks.
Statistical Information
P-Value
0.94
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website